SEC Form 4 · accession 0000914190-19-000066

REGENERX BIOPHARMACEUTICALS INC · RGRX

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — President and CEO · Director

Period of report

Feb 27, 2019

Accepted (ET)

Mar 1, 2019 · 4:47 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0000707511

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock	holding	—	—		—	1,637,991	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Convertible Promissory Note (right to buy)	$0.12	Feb 27, 2019	P	—	A	Feb 27, 2019	Feb 27, 2024	Common Stock	104,167	—	D
Common Stock Warrant (right to buy)	$0.18	Feb 27, 2019	P	78,125	A	Aug 27, 2019	Feb 27, 2024	Common Stock	78,125	78,125	D
Stock Option (right to buy)^F1	$0.16	holding	—	—	—	—	Apr 4, 2019	Common Stock	35,000	35,000	D
Stock Option (right to buy)^F1	$0.57	holding	—	—	—	—	Apr 10, 2019	Common Stock	114,748	114,748	D
Stock Option (right to buy)^F1	$0.21	holding	—	—	—	—	Mar 25, 2021	Common Stock	500,000	500,000	D
Stock Option (right to buy)^F1	$0.36	holding	—	—	—	—	Jun 30, 2022	Common Stock	500,000	500,000	D
Stock Option (right to buy)^F2	$0.64	holding	—	—	—	—	Mar 16, 2023	Common Stock	200,000	200,000	D
Stock Option (right to buy)^F3	$0.28	holding	—	—	—	—	Sep 1, 2027	Common Stock	150,000	150,000	D
Stock Option (Right to Buy)^F4	$0.21	holding	—	—	—	—	Jul 17, 2028	Common Stock	250,000	250,000	D